What Is Tremfya, and Why Does It Matter? Tremfya (guselkumab) is a lab-made, dual-acting antibody medication that reduces inflammation by targeting the interleukin-23 (IL-23) protein and blocking a ...
Tremfya is a brand-name drug used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severely active ulcerative colitis (UC), and Crohn’s disease. Tremfya is given ...
How Does Tremfya Work for Crohn's Disease? Tremfya is a type of medicine called a monoclonal antibody. It works by targeting a protein in your body called interleukin-23 (IL-23). IL-23 is a cytokine ...
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal ...
A greater number of patients treated with subcutaneous TREMFYA ® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA ® ...
TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
Tremfya is used to treat irritable bowel disease (ulcerative colitis and Crohn’s disease) in adults. It’s also approved for plaque psoriasis and psoriatic arthritis in adults and some children.
The lowest effective recommended dosage should be used to maintain therapeutic response. The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adult patients ...
Findings at week 12 showed a significantly greater proportion of patients treated with the SC induction regimen achieved clinical remission compared with those who received placebo. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results